pandem
v
influenza
infect
first
describ
mexico
april
june
world
health
organ
declar
new
flu
first
pandemia
centuri
time
mortal
rate
report
high
similar
rate
report
contin
spain
canada
australia
new
zealand
argentina
efficaci
system
corticosteroid
extens
studi
acut
respiratori
distress
syndrom
ard
clearli
role
situat
ard
precipit
corticosteroidrespons
process
eg
acut
eosinophil
pneumonia
valu
corticosteroid
therapi
case
remain
uncertain
earli
empir
corticosteroid
wide
use
treat
ard
howev
corticosteroid
therapi
set
subsequ
becam
less
frequent
sever
studi
found
benefit
may
actual
caus
harm
sinc
sever
metaanalys
review
publish
offer
conflict
perspect
regard
corticosteroid
treatment
ard
common
pulmonari
present
patient
affect
pandem
v
influenza
infect
rapidli
progress
viral
pneumonia
bilater
alveolar
infiltr
chest
radiographi
ard
present
ard
sever
refractori
hypoxemia
particularli
common
patient
diseas
process
might
link
abnorm
immun
respons
sever
publish
report
pandem
v
influenza
infect
report
use
empir
corticosteroid
therapi
half
patient
primari
therapi
rescu
therapi
patient
sever
ard
recent
guidelin
manag
human
infect
pandem
v
influenza
infect
recommend
corticosteroid
therapi
use
routin
although
low
dose
may
consid
patient
septic
shock
requir
vasopressor
suspect
adren
insuffici
data
support
guidanc
howev
remain
scarc
controversi
singl
prospect
intervent
studi
patient
quispelaim
et
al
demonstr
prolong
low
moder
dose
corticosteroid
treatment
associ
signific
improv
lung
injuri
multipl
organ
dysfunct
score
reduc
hospit
mortal
rate
main
object
studi
therefor
assess
effect
surviv
earli
corticosteroid
therapi
compar
receiv
corticosteroid
receiv
subsequ
rescu
therapi
cohort
patient
hospit
sever
present
pandem
v
influenza
infect
icu
discret
variabl
describ
count
continu
variabl
mean
standard
deviat
sd
median
interquartil
rang
iqr
appropri
unless
otherwis
state
statist
test
two
side
p
consid
signific
differ
categor
variabl
calcul
use
twosid
likelihood
ratio
chisquar
test
fisher
exact
test
u
test
test
use
continu
variabl
appropri
cox
proportionalhazard
regress
analysi
use
assess
impact
independ
variabl
icu
mortal
across
time
variabl
significantli
associ
mortal
univari
analysi
enter
model
avoid
spuriou
associ
variabl
enter
regress
model
relationship
univari
analysi
p
plausibl
relationship
depend
variabl
result
present
hazard
ratio
hr
confid
interv
ci
potenti
explanatori
variabl
check
collinear
prior
inclus
regress
model
use
toler
varianc
inflat
factor
data
analysi
perform
use
spss
spss
chicago
il
usa
window
two
hundr
twenti
patient
complet
outcom
esicm
registri
analyz
studi
patient
suspect
probabl
confirm
pandem
v
influenza
infect
care
icu
one
hundr
ninetyfour
confirm
probabl
patient
suspect
pandem
v
influenza
viru
patient
male
median
age
iqr
year
year
age
mean
score
mean
sofa
score
admiss
mechan
ventil
use
patient
invas
mode
noninvas
patient
noninvas
mode
ventil
subsequ
requir
invas
ventil
patient
receiv
antivir
therapi
oseltamivir
administr
delay
ill
onset
differ
earli
corticosteroid
use
ard
present
patient
comorbid
present
patient
obes
n
asthma
n
chronic
obstruct
pulmonari
diseas
copd
n
main
comorbid
report
one
hundr
twentysix
patient
receiv
earli
corticosteroid
therapi
icu
admiss
patient
surviv
icu
stay
receiv
corticosteroid
earli
icu
admiss
mean
durat
corticosteroid
therapi
day
icu
length
stay
survivor
differ
patient
receiv
earli
corticosteroid
compar
versu
day
p
patient
receiv
earli
corticosteroid
therapi
significantli
older
versu
year
p
asthma
versu
p
copd
versu
p
chronic
steroid
use
versu
p
frequent
patient
patient
receiv
earli
corticosteroid
therapi
sicker
receiv
accord
data
versu
p
differ
found
patient
treat
earli
corticosteroid
therapi
regard
preval
ard
versu
p
mechan
ventil
base
lung
protect
strategi
entir
cohort
tidal
volum
iqr
mlkg
ideal
bodi
weight
ibw
find
differ
tidal
volum
patient
receiv
earli
corticosteroid
therapi
compar
iqr
versu
iqr
mlkg
ibw
p
addit
demograph
data
clinic
characterist
patient
pandem
v
influenza
without
earli
corticosteroid
therapi
present
tabl
hospitalacquir
pneumonia
clinic
suspect
patient
microbiolog
document
patient
patient
patient
receiv
earli
corticosteroid
therapi
hap
frequent
patient
versu
p
odd
ratio
ci
sinc
sever
ill
patient
receiv
earli
corticosteroid
therapi
higher
multivari
regress
analysi
adjust
sever
perform
confirm
higher
incid
hap
patient
receiv
earli
corticosteroid
therapi
confid
interv
ci
p
pseudomona
aeruginosa
n
identifi
preval
pathogen
follow
acinetobact
baumannii
n
streptococcu
pneumonia
n
tabl
total
patient
die
icu
whilst
hospit
nonsurvivor
present
significantli
higher
score
admiss
versu
p
higher
sofa
score
versu
p
compar
survivor
characterist
patient
die
shown
tabl
patient
receiv
earli
corticosteroid
therapi
icu
admiss
significantli
higher
icu
mortal
versu
ci
p
associ
increas
mortal
present
mortal
data
adjust
increas
sever
ill
known
confound
variabl
age
copd
asthma
chronic
steroid
use
hazard
ratio
hr
ci
p
fig
similar
find
found
repeat
analysi
cohort
patient
present
ard
hr
ci
p
analysi
larg
cohort
prospect
multicent
research
studi
suggest
prompt
use
corticosteroid
therapi
icu
admiss
result
reduct
mortal
critic
ill
patient
admit
pandem
v
influenza
infect
furthermor
also
benefici
effect
earli
corticosteroid
therapi
given
sever
end
spectrum
patient
requir
invas
mechan
ventil
ard
anoth
import
find
studi
patient
receiv
earli
corticosteroid
therapi
increas
likelihood
develop
superad
bacteri
infect
endogen
glucocorticoid
endeffector
play
role
inhibit
inflamm
alway
effect
suppress
cytokin
storm
driven
system
inflamm
even
though
cortisol
level
correl
grade
ill
sever
mortal
concept
criticalillnessrel
corticosteroid
insuffici
circi
result
clinic
trial
show
respiratori
immun
hemodynam
benefit
corticosteroid
therapi
reemerg
promis
adjunct
treatment
sever
sepsi
sever
bacteri
pneumonia
associ
rel
corticosteroid
insuffici
well
plethora
pulmonari
system
effect
inflammatori
cascad
partial
block
administr
system
corticosteroid
therapi
sever
present
wors
inflammatori
crisi
therefor
previou
author
suggest
steroid
therapi
effect
sever
ill
patient
shown
present
studi
recent
guidelin
manag
communityacquir
pneumonia
suggest
benefit
system
corticosteroid
therapi
patient
sever
present
shown
one
small
random
control
studi
hydrocortison
treatment
termin
prematur
due
mortal
intervent
arm
signific
reduct
length
hospit
stay
recent
snijder
et
al
conduct
random
control
trial
hospit
patient
cap
patient
random
receiv
either
mg
prednisolon
day
placebo
ad
antibiot
therapi
studi
show
differ
clinic
outcom
either
overal
popul
sever
pneumonia
addit
late
clinic
failur
h
hospit
admiss
common
prednisolon
group
placebo
group
data
support
use
corticosteroid
therapi
patient
affect
primari
viral
pneumonia
limit
present
time
report
extrapol
sever
acut
respiratori
syndrom
coronaviru
sarscov
outbreak
current
pandem
innat
antivir
host
respons
base
earli
elev
express
sarscov
human
respiratori
syncyti
viru
hrsv
infect
patient
use
corticosteroid
therapi
doubleedg
sword
li
et
al
report
high
dose
corticosteroid
decreas
immun
reduc
level
patient
sar
result
increas
secondari
infect
moreov
tsang
et
al
found
increas
mortal
subset
patient
nevertheless
exact
mechan
corticosteroid
therapi
need
elucid
due
fact
evid
benefit
sar
earli
phase
sarscov
replic
still
ongo
lee
et
al
found
sarscov
load
significantli
higher
second
third
week
ill
patient
receiv
initi
corticosteroid
therapi
recent
result
corticu
studi
support
routin
use
corticosteroid
therapi
patient
septic
shock
show
benefici
effect
stress
dose
corticosteroid
decreas
time
shock
revers
mortal
effect
least
part
explain
increas
risk
superinfect
use
corticosteroid
therapi
also
exert
decis
influenc
immun
function
macrophag
granulocyt
main
cell
host
defens
bacteria
present
studi
signific
incid
nosocomi
infect
result
twofold
higher
incid
hospitalacquir
pneumonia
patient
receiv
corticosteroid
therapi
incid
hap
due
pseudomona
aeruginosa
due
acinetobact
baumannii
corticosteroid
group
addit
one
intrigu
observ
four
patient
develop
ventilatorassoci
pneumonia
vap
due
aspergillu
spp
three
receiv
corticosteroid
therapi
present
studi
sever
potenti
limit
address
first
patient
treat
earli
corticosteroid
therapi
icu
admiss
consid
treatment
group
control
group
compris
patient
receiv
earli
corticosteroid
therapi
receiv
subsequ
rescu
therapi
use
corticosteroid
therapi
icu
admiss
consid
treatment
group
sinc
subgroup
patient
would
consid
receiv
rescu
therapi
due
unfavor
clinic
progress
data
avail
subanalyz
role
rescu
therapi
nevertheless
multivari
analysi
adjust
sever
well
confound
factor
avoid
potenti
bia
might
invalid
final
conclus
secondli
observ
nonintervent
studi
particip
icu
countri
world
selfselect
prescript
corticosteroid
chosen
accord
local
protocol
correct
differ
differ
corticosteroid
therapi
treatment
class
homogen
system
corticosteroid
use
consid
dosag
equival
mgday
methylprednison
mgday
prednison
given
acut
icu
admiss
report
previou
studi
thirdli
spite
fact
microbiolog
confirm
base
current
infecti
diseas
societi
america
idsa
american
thorac
societi
at
guidelin
would
prefer
bronchoscop
procedur
perform
routin
sever
hypoxemia
complic
ard
v
episod
safeti
concern
regard
gener
aerosol
final
dose
oseltamivir
left
discret
attend
physician
standard
crucial
note
underdos
common
problem
patient
sever
sepsi
mechan
ventil
high
volum
distribut
low
enter
absorpt
ariano
et
al
recent
report
dosag
mg
twicedaili
achiev
plasma
level
compar
ambulatori
patient
far
excess
concentr
requir
maxim
inhibit
neuraminidas
activ
viru
littl
definit
evid
either
benefit
harm
earli
corticosteroid
use
routin
adjunct
treatment
patient
affect
pandem
v
influenza
infect
nevertheless
result
drawn
studi
show
earli
use
result
better
outcom
may
associ
increas
risk
superad
infect
